Oncology Intelligence Digest August 07, 2026 The FDA granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec, RP1) for…
Oncology Intelligence Membership Required
You must be a Oncology Intelligence member to access this content.
Already a member? Log in here